Esperion Therapeutics, a biotech firm developing new drugs that exploit the role of high density lipoproteins (HDLs) to reduce arterial plaque, priced its offering of 6mm shares at $9, the mid-point of its $8-10 range. Trading in the stock will begin Thursday. Robertson Stephens is the lead underwriter.
